Barrier function of the nasal mucosa in health and type-2 biased airway diseases

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 71, Issue 3, 2016, Pages 295-307

  Zhang, N ^a   Van Crombruggen, K ^a   Gevaert, E ^a   Bachert, C ^a,b  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

allergic rhinitis; chronic rhinosinusitis with nasal polyps; eosinophil extracellular traps; immune response; nasal epithelial barrier

Indexed keywords

ANTIINFECTIVE AGENT; CHEMOKINE; CYTOKINE; DUPILUMAB; GLUCOCORTICOID; OMALIZUMAB; ANTIMICROBIAL CATIONIC PEPTIDE;

ADAPTIVE IMMUNITY; ALLERGIC RHINITIS; ASTHMA; BRONCHITIS; EOSINOPHIL; HUMAN; IMMUNOMODULATION; INFECTION; INFLAMMATION; INNATE IMMUNITY; LYMPHOID CELL; MICROBIOME; MUCOCILIARY CLEARANCE; NOSE MUCOSA; NOSE POLYP; PRIORITY JOURNAL; RESPIRATORY EPITHELIUM; RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT MUCOSA; REVIEW; TH1 CELL; TH17 CELL; ANIMAL; EXTRACELLULAR TRAP; HYPERSENSITIVITY; IMMUNOLOGY; METABOLISM; MICROBIOLOGY; MICROFLORA; MUCOSAL IMMUNITY; NEUTROPHIL; RESPIRATORY TRACT INFECTIONS;

ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; CHEMOKINES; CYTOKINES; EOSINOPHILS; EXTRACELLULAR TRAPS; HUMANS; HYPERSENSITIVITY; IMMUNITY, INNATE; IMMUNITY, MUCOSAL; MICROBIOTA; NASAL MUCOSA; NEUTROPHILS; RESPIRATORY TRACT INFECTIONS;

EID: 84957436413     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12809     Document Type: Review

References (108)

1. Xiao C, Puddicombe SM, Field S, Haywood J, Broughton-Head V, Puxeddu I, et al., Defective epithelial barrier function in asthma. J Allergy Clin Immunol 2011; 128: 549-556.
2. Soyka MB, Wawrzyniak P, Eiwegger T, Holzmann D, Treis A, Wanke K, et al., Defective epithelial barrier in chronic rhinosinusitis: the regulation of tight junctions by IFN-γ and IL-4. J Allergy Clin Immunol 2012; 130: 1087-1096.
3. Yasuda M, Niisato N, Miyazaki H, Hama T, Dejima K, Hisa Y, et al., Epithelial ion transport of human nasal polyp and paranasal sinus mucosa. Am J Respir Cell Mol Biol 2007; 36: 466-472.
4. Yasuda M, Niisato N, Miyazaki H, Iwasaki Y, Hama T, Dejima K, et al., Epithelial Na+ channel and ion transport in human nasal polyp and paranasal sinus mucosa. Biochem Biophys Res Commun 2007; 362: 753-758.
5. Kojima T, Go M, Takano K, Kurose M, Ohkuni T, Koizumi J, et al., Regulation of tight junctions in upper airway epithelium. Biomed Res Int 2013; 2013: 947072.
6. Suzuki M, Itoh M, Ohta N, Nakamura Y, Moriyama A, Matsumoto T, et al., Blocking of protease allergens with inhibitors reduces allergic responses in allergic rhinitis and other allergic diseases. Acta Otolaryngol 2006; 126: 746-751.
7. Pothoven K, Norton JE, Hulse KE, Suh LA, Carter RG, Rocci E, et al., Oncostatin M promotes mucosal epithelial barrier dysfunction, and its expression is increased in patients with eosinophilic mucosal disease. J Allergy Clin Immunol 2015; 136: 737-746.
8. Gudis D, Zhao KQ, Cohen NA,. Acquired cilia dysfunction in chronic rhinosinusitis. Am J Rhinol Allergy 2012; 26: 1-6.
9. Vlastos I, Athanasopoulos I, Mastronikolis NS, Panogeorgou T, Margaritis V, Naxakis S, et al., Impaired mucociliary clearance in allergic rhinitis patients is related to a predisposition to rhinosinusitis. Ear Nose Throat J 2009; 88: E17-E19.
10. Melvin TA, Ramanathan M Jr,. Role of innate immunity in the pathogenesis of allergic rhinitis. Curr Opin Otolaryngol Head Neck Surg 2012; 20: 194-198.
11. Seshadri S, Lin DC, Rosati M, Carter RG, Norton JE, Suh L, et al., Reduced expression of antimicrobial PLUNC proteins in nasal polyp tissues of patients with chronic rhinosinusitis. Allergy 2012; 67: 920-928.
12. Ramanathan M Jr, Lee WK, Spannhake EW, Lane AP,. Th2 cytokines associated with chronic rhinosinusitis with polyps down-regulate the antimicrobial immune function of human sinonasal epithelial cells. Am J Rhinol 2008; 22: 115-121.
13. Lee RJ, Cohen NA,. Role of the bitter taste receptor T2R38 in upper respiratory infection and chronic rhinosinusitis. Curr Opin Allergy Clin Immunol 2015; 15: 14-20.
14. Lee RJ, Xiong G, Kofonow JM, Chen B, Lysenko A, Jiang P, et al., T2R38 taste receptor polymorphisms underlie susceptibility to upper respiratory infection. J Clin Invest 2012; 122: 4145-4159.
15. Lan F, Wang XD, Nauwynck JH, Holtappels G, Zhang L, Johnston LS, et al., Th2 biased upper airway inflammation is associated with an impaired response to viral infection with Herpes simplex virus 1. Rhinology 2015, Dec 23. [Epub ahead of print]. http://www.ncbi.nlm.nih.gov/pubmed/26702454
16. Wang X, Zhang N, Glorieux S, Holtappels G, Vaneechoutte M, Krysko O, et al., Herpes simplex virus type 1 infection facilitates invasion of Staphylococcus aureus into the nasal mucosa and nasal polyp tissue. PLoS One 2012; 7: e39875.
17. Krysko O, Holtappels G, Zhang N, Kubica M, Deswarte K, Derycke L, et al., Alternatively activated macrophages and impaired phagocytosis of S. aureus in chronic rhinosinusitis. Allergy 2011; 66: 396-403.
18. Ursell LK, Clemente JC, Rideout JR, Gevers D, Caporaso JG, Knight R,. The interpersonal and intrapersonal diversity of human-associated microbiota in key body sites. J Allergy Clin Immunol 2012; 129: 1204-1208.
19. Abrahamsson TR, Jakobsson HE, Andersson AF, Bjorksten B, Engstrand L, Jenmalm MC,. Low gut microbiota diversity in early infancy precedes asthma at school age. Clin Exp Allergy 2014; 44: 842-850.
20. Bisgaard H, Li N, Bonnelykke K, Chawes BL, Skov T, Paludan-Muller G, et al., Reduced diversity of the intestinal microbiota during infancy is associated with increased risk of allergic disease at school age. J Allergy Clin Immunol 2011; 128: 646-652.
21. Herbst T, Sichelstiel A, Schar C, Yadava K, Burki K, Cahenzli J, et al., Dysregulation of allergic airway inflammation in the absence of microbial colonization. Am J Respir Crit Care Med 2011; 184: 198-205.
22. Marsland BJ,. Regulation of inflammatory responses by the commensal microbiota. Thorax 2012; 67: 93-94.
23. Feazel LM, Robertson CE, Ramakrishnan VR, Frank DN,. Microbiome complexity and staphylococcus aureus in chronic rhinosinusitis. Laryngoscope 2012; 122: 467-472.
24. Choi EB, Hong SW, Kim DK, Jeon SG, Kim KR, Cho SH, et al., Decreased diversity of nasal microbiota and their secreted extracellular vesicles in patients with chronic rhinosinusitis based on a metagenomic analysis. Allergy 2014; 69: 517-526.
25. Ba L, Zhang N, Meng J, Zhang J, Lin P, Zhou P, et al., Bacterial colonization is associated with different inflammatory pattern in rhinosinusitis with nasal polyps. Allergy 2011; 66: 1296-1303.
26. Bachert C, Zhang N,. Chronic rhinosinusitis and asthma: novel understanding of the role of IgE "above atopy". J Intern Med 2012; 272: 133-143.
27. Corriveau MN, Zhang N, Holtappels G, Van Roy N, Bachert C,. Detection of Staphylococcus aureus in nasal tissue with peptide nucleic acid-fluorescence in situ hybridization. Am J Rhinol Allergy 2009; 23: 461-465.
28. Kaliner M, Marom Z, Patow C, Shelhamer J,. Human respiratory mucus. J Allergy Clin Immunol 1984; 73: 318-323.
29. Groneberg DA, Peiser C, Dinh QT, Matthias J, Eynott PR, Heppt W, et al., Distribution of respiratory mucin proteins in human nasal mucosa. Laryngoscope 2003; 113: 520-524.
30. Voynow JA, Gendler SJ, Rose MC,. Regulation of mucin genes in chronic inflammatory airway diseases. Am J Respir Cell Mol Biol 2006; 34: 661-665.
31. Song SY, Chi DH, Bae CH, Kim YD,. Staphylococcus enterotoxin A induces MUC5B expression via Toll-like receptor 2, extracellular signal-regulated kinase 1/2, and p38 mitogen-activated protein kinase in human airway epithelial cells. Am J Rhinol Allergy 2014; 28: e25-e30.
32. Fahy JV, Dickey BF,. Airway mucus function and dysfunction. N Engl J Med 2010; 363: 2233-2247.
33. Zhang Y, Wang X, Wang H, Jiao J, Li Y, Fan E, et al., TMEM16A-mediated mucin secretion in IL-13-induced nasal epithelial cells from chronic rhinosinusitis patients. Allergy Asthma Immunol Res 2015; 7: 367-375.
34. Marchiando AM, Graham WV, Turner JR,. Epithelial barriers in homeostasis and disease. Annu Rev Pathol 2010; 5: 119-144.
35. Meng J, Zhou P, Liu Y, Liu F, Yi X, Liu S, et al., The development of nasal polyp disease involves early nasal mucosal inflammation and remodelling. PLoS One 2013; 8: e82373.
36. Vinhas R, Cortes L, Cardoso I, Mendes VM, Manadas B, Todo-Bom A, et al., Pollen proteases compromise the airway epithelial barrier through degradation of transmembrane adhesion proteins and lung bioactive peptides. Allergy 2011; 66: 1088-1098.
37. Tai HY, Tam MF, Chou H, Peng HJ, Su SN, Perng DW, et al., Pen ch 13 allergen induces secretion of mediators and degradation of occludin protein of human lung epithelial cells. Allergy 2006; 61: 382-388.
38. Doss M, White MR, Tecle T, Hartshorn KL,. Human defensins and LL-37 in mucosal immunity. J Leukoc Biol 2010; 87: 79-92.
39. Ramanathan M Jr, Lee WK, Dubin MG, Lin S, Spannhake EW, Lane AP,. Sinonasal epithelial cell expression of toll-like receptor 9 is decreased in chronic rhinosinusitis with polyps. Am J Rhinol 2007; 21: 110-116.
40. Nonaka M, Ogihara N, Fukumoto A, Sakanushi A, Pawankar R, Yagi T,. Toll-like receptor 2, 3, 4, 5 ligands and interleukin-4 synergistically induce TARC production in nasal polyp fibroblasts. Auris Nasus Larynx 2008; 35: 515-520.
41. Pitzurra L, Bellocchio S, Nocentini A, Bonifazi P, Scardazza R, Gallucci L, et al., Antifungal immune reactivity in nasal polyposis. Infect Immun 2004; 72: 7275-7281.
42. Claeys S, De Belder T, Holtappels G, Gevaert P, Verhasselt B, van Cauwenberge P, et al., Human beta-defensins and toll-like receptors in the upper airway. Allergy 2003; 58: 748-753.
43. Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T, et al., Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002; 347: 1151-1160.
44. Bachert C, Zhang N, van Zele T, Gevaert P, Patou J, van Cauwenberge P,. Staphylococcus aureus enterotoxins as immune stimulants in chronic rhinosinusitis. Clin Allergy Immunol 2007; 20: 163-175.
45. Nayak A, Dodagatta-Marri E, Tsolaki AG, Kishore U,. An insight into the diverse roles of surfactant proteins, SP-A and SP-D in innate and adaptive immunity. Front Immunol 2012; 3: 131.
46. Woodworth BA, Wood R, Baatz JE, Schlosser RJ,. Sinonasal surfactant protein A1, A2, and D gene expression in cystic fibrosis: a preliminary report. Otolaryngol Head Neck Surg 2007; 137: 34-38.
47. Ooi EH, Wormald PJ, Carney AS, James CL, Tan LW,. Surfactant protein d expression in chronic rhinosinusitis patients and immune responses in vitro to Aspergillus and alternaria in a nasal explant model. Laryngoscope 2007; 117: 51-57.
48. Chong KT, Thangavel RR, Tang X,. Enhanced expression of murine beta-defensins (MBD-1, -2,- 3, and -4) in upper and lower airway mucosa of influenza virus infected mice. Virology 2008; 380: 136-143.
49. Corbin BD, Seeley EH, Raab A, Feldmann J, Miller MR, Torres VJ, et al., Metal chelation and inhibition of bacterial growth in tissue abscesses. Science 2008; 319: 962-965.
50. Bryborn M, Adner M, Cardell LO,. Psoriasin, one of several new proteins identified in nasal lavage fluid from allergic and non-allergic individuals using 2-dimensional gel electrophoresis and mass spectrometry. Respir Res 2005; 6: 118.
51. Bryborn M, Hallden C, Sall T, Adner M, Cardell LO,. Comprehensive evaluation of genetic variation in S100A7 suggests an association with the occurrence of allergic rhinitis. Respir Res 2008; 9: 29.
52. Kvarnhammar AM, Rydberg C, Jarnkrants M, Eriksson M, Uddman R, Benson M, et al., Diminished levels of nasal S100A7 (psoriasin) in seasonal allergic rhinitis: an effect mediated by Th2 cytokines. Respir Res 2012; 13: 2.
53. Biragyn A, Ruffini PA, Leifer CA, Klyushnenkova E, Shakhov A, Chertov O, et al., Toll-like receptor 4-dependent activation of dendritic cells by beta-defensin 2. Science 2002; 298: 1025-1029.
54. Funderburg N, Lederman MM, Feng Z, Drage MG, Jadlowsky J, Harding CV, et al., Human -defensin-3 activates professional antigen-presenting cells via Toll-like receptors 1 and 2. Proc Natl Acad Sci USA 2007; 104: 18631-18635.
55. Ohya M, Nishitani C, Sano H, Yamada C, Mitsuzawa H, Shimizu T, et al., Human pulmonary surfactant protein D binds the extracellular domains of Toll-like receptors 2 and 4 through the carbohydrate recognition domain by a mechanism different from its binding to phosphatidylinositol and lipopolysaccharide. Biochemistry 2006; 45: 8657-8664.
56. Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, van Zoelen MA, et al., Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med 2007; 13: 1042-1049.
57. Van Crombruggen K, Vogl T, Perez-Novo CA, Holtappels G, Bachert C,. Differential release and deposition of S100A8/A9 proteins in inflamed upper airway tissue. Eur Respir J 2016; 47: 264-274.
58. Tieu DD, Peters AT, Carter RG, Suh L, Conley DB, Chandra R, et al., Evidence for diminished levels of epithelial psoriasin and calprotectin in chronic rhinosinusitis. J Allergy Clin Immunol 2010; 125: 667-675.
59. Rosenberg HF,. Eosinophil-derived neurotoxin/RNase 2: connecting the past, the present and the future. Curr Pharm Biotechnol 2008; 9: 135-140.
60. Yang D, Chen Q, Su SB, Zhang P, Kurosaka K, Caspi RR, et al., Eosinophil-derived neurotoxin acts as an alarmin to activate the TLR2-MyD88 signal pathway in dendritic cells and enhances Th2 immune responses. J Exp Med 2008; 205: 79-90.
61. Kalfa VC, Spector SL, Ganz T, Cole AM,. Lysozyme levels in the nasal secretions of patients with perennial allergic rhinitis and recurrent sinusitis. Ann Allergy Asthma Immunol 2004; 93: 288-292.
62. Bascom R, Pipkorn U, Proud D, Dunnette S, Gleich GJ, Lichtenstein LM, et al., Major basic protein and eosinophil-derived neurotoxin concentrations in nasal-lavage fluid after antigen challenge: effect of systemic corticosteroids and relationship to eosinophil influx. J Allergy Clin Immunol 1989; 84: 338-346.
63. Alvarado-Valdes CA, Blomgren J, Weiler D, Gleich GJ, Reed CE, Field EA, et al., The effect of fluticasone propionate aqueous nasal spray on eosinophils and cytokines in nasal secretions of patients with ragweed allergic rhinitis. Clin Ther 1997; 19: 273-281.
64. Van Crombruggen K, Zhang N, Gevaert P, Tomassen P, Bachert C,. Pathogenesis of chronic rhinosinusitis: inflammation. J Allergy Clin Immunol 2011; 128: 728-732.
65. Dhirapong A, Lleo A, Leung P, Gershwin ME, Liu FT,. The immunological potential of galectin-1 and -3. Autoimmun Rev 2009; 8: 360-363.
66. Fernandes AM, Babeto E, Rahal P, Provazzi PJ, Hidalgo CA, Anselmo-Lima WT,. Expression of genes that encode the annexin-1 and galectin-1 proteins in nasal polyposis and their modulation by glucocorticoid. Braz J Otorhinolaryngol 2010; 76: 213-218.
67. Delbrouck C, Gabius HJ, Kaltner H, Decaestecker C, Kiss R, Hassid S,. Expression patterns of galectin-1 and galectin-3 in nasal polyps and middle and inferior turbinates in relation to growth regulation and immunosuppression. Arch Otolaryngol Head Neck Surg 2003; 129: 665-669.
68. Han JL, Ding RY, Zhao L, Ren Z, Jiang XJ,. Rosiglitazone attenuates allergic inflammation and inhibits expression of galectin-3 in a mouse model of allergic rhinitis. J Int Med Res 2008; 36: 830-836.
69. Negrete-Garcia MC, Jimenez-Torres CY, Alvarado-Vasquez N, Montes-Vizuet AR, Velazquez-Rodriguez JR, Jimenez-Martinez MC, et al., Galectin-10 is released in the nasal lavage fluid of patients with aspirin-sensitive respiratory disease. Sci World J 2012; 2012: 6.
70. Bryborn M, Mansson A, Cardell LO, Adner M,. Differentiated S100A7 expression in infected tonsils and tonsils from allergic individuals. FEMS Immunol Med Microbiol 2008; 53: 413-420.
71. Sonnenberg GF, Mjosberg J, Spits H, Artis D,. SnapShot: innate lymphoid cells. Immunity 2013; 39: 622.
72. Bernink JH, Peters CP, Munneke M, te Velde AA, Meijer SL, Weijer K, et al., Human type 1 innate lymphoid cells accumulate in inflamed mucosal tissues. Nat Immunol 2013; 14: 221-229.
73. Halim TY, Krauss RH, Sun AC, Takei F,. Lung natural helper cells are a critical source of Th2 cell-type cytokines in protease allergen-induced airway inflammation. Immunity 2012; 36: 451-463.
74. Mjosberg JM, Trifari S, Crellin NK, Peters CP, van Drunen CM, Piet B, et al., Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161. Nat Immunol 2011; 12: 1055-1062.
75. Miljkovic D, Bassiouni A, Cooksley C, Ou J, Hauben E, Wormald PJ, et al., Association between group 2 innate lymphoid cells enrichment, nasal polyps and allergy in chronic rhinosinusitis. Allergy 2014; 69: 1154-1161.
76. Ho J, Bailey M, Zaunders J, Mrad N, Sacks R, Sewell W, et al., Group 2 innate lymphoid cells (ILC2s) are increased in chronic rhinosinusitis with nasal polyps or eosinophilia. Clin Exp Allergy 2015; 45: 394-403.
77. Walford HH, Lund SJ, Baum RE, White AA, Bergeron CM, Husseman J, et al., Increased ILC2s in the eosinophilic nasal polyp endotype are associated with corticosteroid responsiveness. Clin Immunol 2014; 155: 126-135.
78. Reh DD, Wang Y, Ramanathan M Jr, Lane AP,. Treatment-recalcitrant chronic rhinosinusitis with polyps is associated with altered epithelial cell expression of interleukin-33. Am J Rhinol Allergy 2010; 24: 105-109.
79. Kouzaki H, Iijima K, Kobayashi T, O'Grady SM, Kita H,. The danger signal, extracellular ATP, is a sensor for an airborne allergen and triggers IL-33 release and innate Th2-type responses. J Immunol 2011; 186: 4375-4387.
80. Shaw JL, Fakhri S, Citardi MJ, Porter PC, Corry DB, Kheradmand F, et al., IL-33-responsive innate lymphoid cells are an important source of IL-13 in chronic rhinosinusitis with nasal polyps. Am J Respir Crit Care Med 2013; 188: 432-439.
81. Bartemes KR, Kephart GM, Fox SJ, Kita H,. Enhanced innate type 2 immune response in peripheral blood from patients with asthma. J Allergy Clin Immunol 2014; 134: 671-678.
82. Gandhi VD, Vliagoftis H,. Airway epithelium interactions with aeroallergens: role of secreted cytokines and chemokines in innate immunity. Front Immunol 2015; 6: 147.
83. Contoli M, Ito K, Padovani A, Poletti D, Marku B, Edwards MR, et al., Th2 cytokines impair innate immune responses to rhinovirus in respiratory epithelial cells. Allergy 2015; 70: 910-920.
84. Jackson DJ, Makrinioti H, Rana BM, Shamji BW, Trujillo-Torralbo MB, Footitt J, et al., IL-33-dependent type 2 inflammation during rhinovirus-induced asthma exacerbations in vivo. Am J Respir Crit Care Med 2014; 190: 1373-1382.
85. Huvenne W, Callebaut I, Reekmans K, Hens G, Bobic S, Jorissen M, et al., Staphylococcus aureus enterotoxin B augments granulocyte migration and survival via airway epithelial cell activation. Allergy 2010; 65: 1013-1020.
86. Lan F, Zhang N, Holtappels G, Ruyck ND, Krysko O, van Crombruggen K, et al., Staphyloccoccus aureus induces type 2 cytokines via TSLP and IL-33 release in human airway mucosa. In press.
87. Dworski R, Simon HU, Hoskins A, Yousefi S,. Eosinophil and neutrophil extracellular DNA traps in human allergic asthmatic airways. J Allergy Clin Immunol 2011; 127: 1260-1266.
88. Yousefi S, Gold JA, Andina N, Lee JJ, Kelly AM, Kozlowski E, et al., Catapult-like release of mitochondrial DNA by eosinophils contributes to antibacterial defense. Nat Med 2008; 14: 949-953.
89. Yousefi S, Simon D, Simon HU,. Eosinophil extracellular DNA traps: molecular mechanisms and potential roles in disease. Curr Opin Immunol 2012; 24: 736-739.
90. Simon D, Radonjic-Hösli S, Straumann A, Yousefi S, Simon HU, et al., Active eosinophilic esophagitis is characterized by epithelial barrier defects and eosinophil extracellular trap formation. Allergy 2015; 70: 443-452.
91. Thammavongsa V, Missiakas DM, Schneewind O,. Staphylococcus aureus degrades neutrophil extracellular traps to promote immune cell death. Science 2013; 342: 863-866.
92. Minai-Fleminger Y, Gangwar RS, Migalovich-Sheikhet H, Seaf M, Leibovici V, Hollander N, et al., The CD48 receptor mediates Staphylococcus aureus human and murine eosinophil activation. Clin Exp Allergy 2014; 44: 1335-1346.
93. Morshed M, Yousefi S, Stöckle C, Simon HU, Simon D,. Thymic stromal lymphopoietin stimulates the formation of eosinophil extracellular traps. Allergy 2012; 67: 1127-1137.
94. Vlaminck S, Vauterin T, Hellings PW, Jorissen M, Acke F, Van Cauwenberge P, et al., The importance of local eosinophilia in the surgical outcome of chronic rhinosinusitis: a 3-year prospective observational study. Am J Rhinol Allergy 2014; 28: 260-264.
95. Rottiers P, De Smedt T, Steidler L,. Modulation of gut-associated lymphoid tissue functions with genetically modified Lactococcus lactis. Int Rev Immunol 2009; 28: 465-486.
96. Vandersteegen K, Mattheus W, Ceyssens PJ, Bilocq F, De Vos D, Pirnay JP, et al., Microbiological and molecular assessment of bacteriophage ISP for the control of Staphylococcus aureus. PLoS One 2011; 6: e24418.
97. McMichael JW, Maxwell AI, Hayashi K, Taylor K, Wallace WA, Govan JR, et al., Antimicrobial activity of murine lung cells against Staphylococcus aureus is increased in vitro and in vivo after elafin gene transfer. Infect Immun 2005; 73: 3.
98. Domingues M, Silva P, Franquelim H, Carvalho F, Castanho M,. SantosN. Antimicrobial protein rBPI21-induced surface changes on Gram-negative and Gram-positive bacteria. Nanomedicine 2014; 10: 543-551.
99. Grumann D, Nubel U, Bröker MK,. Staphylococcus aureus toxins-their functions and genetics. Infect Genet Evol 2014; 21: 583-592.
100. Hong-Geller E, Möllhoff M, Shiflett P, Gupta G,. Design of chimeric receptor mimics with different TcR Vbeta isoforms. Type-specific inhibition of superantigen pathogenesis. J Biol Chem 2004; 279: 5676-5684.
101. Minshall E, Ghaffar O, Cameron L, O'Brien F, Quinn H, Rowe-Jones J, et al., Assessment by nasal biopsy of long-term use of mometasone furoate aqueous nasal spray (Nasonex) in the treatment of perennial rhinitis. Otolaryngol Head Neck Surg 1998; 118: 648-654.
102. Caluwaerts S, Vandenbroucke K, Steidler L, Neirynck S, Vanhoenacker P, Corveleyn S, et al., AG013, a mouth rinse formulation of Lactococcus lactis secreting human Trefoil Factor 1, provides a safe and efficacious therapy tool for treating oral mucositis. Oral Oncol 2010; 46: 564-570.
103. Duechs M, Hahn C, Benediktus E, Werner-Klein M, Braun A, Hoymann H, et al., TLR agonist mediated suppression of allergic responses is associated with increased innate inflammation in the airways. Pulm Pharmacol Ther 2011; 24: 203-214.
104. Gauvreau GM, O'Byrne PM, Boulet LP, Wang Y, Cockcroft D, Bigler J, et al., Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med 2014; 370: 2102-2110.
105. Gevaert P, Van Bruaene N, Cattaert T, Van Steen K, Van Zele T, Acke F, et al., Mepolizumab, a humanised anti-IL-5 monoclonal antibody, as treatment option for severe nasal polyposis. J Allergy Clin Immunol 2011; 128: 989-995.
106. Bachert C, Mannent L, Naclerio MR, Mullol J, Ferguson JB, Gevaert P, et al., Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis With Nasal Polyposis Refractory to Intranasal Corticosteroids. A Randomized Clinical Trial. JAMA 2016 in press.
107. Krug N, Hohlfeld JM, Kirsten AM, Kornmann O, Beeh K, Kappeler D, et al., Allergen-induced asthmatic responses modified by a GATA-3 specific DNAzyme. N Engl J Med 2015; 372: 1987-1995.
108. Gevaert P, Calus L, Van Zele T, Blomme K, De Ruyck N, Bauters W, et al., Omalizumab is effective in allergic and non-allergic patients with nasal polyposis and co-morbid asthma. J Allergy Clin Immunol 2013; 131: 110-116.